Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) EBITDA (2022 - 2026)

Centessa Pharmaceuticals has reported EBITDA over the past 4 years, most recently at -$66.0 million for Q4 2025.

  • Quarterly EBITDA rose 39.52% to -$66.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$199.0 million through Dec 2025, up 14.59% year-over-year, with the annual reading at -$199.0 million for FY2025, 14.59% up from the prior year.
  • EBITDA was -$66.0 million for Q4 2025 at Centessa Pharmaceuticals, down from -$53.9 million in the prior quarter.
  • Over five years, EBITDA peaked at -$23.3 million in Q2 2023 and troughed at -$109.2 million in Q4 2024.
  • The 4-year median for EBITDA is -$46.8 million (2023), against an average of -$49.9 million.
  • Year-over-year, EBITDA soared 64.52% in 2023 and then plummeted 202.33% in 2024.
  • A 4-year view of EBITDA shows it stood at -$43.0 million in 2022, then rose by 15.94% to -$36.1 million in 2023, then plummeted by 202.33% to -$109.2 million in 2024, then soared by 39.52% to -$66.0 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's EBITDA are -$66.0 million (Q4 2025), -$53.9 million (Q3 2025), and -$50.8 million (Q2 2025).